All Fields
Computer Science
Medicine
FAQ
Contact
Sign in
DMP 696
Known as:
4-(1,3-dimethoxy-2-propylamino)-2,7-dimethyl-8-(2,4-dichlorophenyl)(1,5-a)pyrazolo-1,3,5-triazine
, DMP-696
, DMP696
Â
Â
Topic mentions per year
Topic mentions per year
2000-2012
0
1
2
3
2000
2012
Related topics
Related topics
2 relations
Broader (2)
Pyrazoles
Triazines
Related mentions per year
Related mentions per year
1947-2018
1940
1960
1980
2000
2020
DMP 696
Triazines
Pyrazoles
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Consolidation of Remote Fear Memories Involves Corticotropin-Releasing Hormone (CRH) Receptor Type 1-Mediated Enhancement of AMPA Receptor GluR1 Signaling in the Dentate Gyrus
Christoph K. Thoeringer
,
Kathrin Henes
,
+6 authors
Carsten Tobias Wotjak
Neuropsychopharmacology
2012
Persistent dreadful memories and hyperarousal constitute prominent psychopathological features of posttraumatic stress disorder…Â
(More)
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Persistent neuroendocrine and behavioral effects of a novel, etiologically relevant mouse paradigm for chronic social stress during adolescence.
Mathias V Schmidt
,
Vera Sterlemann
,
+7 authors
Michael Müller
Psychoneuroendocrinology
2007
Chronic stress is widely regarded as a key risk factor for a variety of diseases. A large number of paradigms have been used to…Â
(More)
Is this relevant?
2007
2007
Activation of basolateral amygdala corticotropin-releasing factor 1 receptors modulates the consolidation of contextual fear.
Dan Hubbard
,
Brandy R Nakashima
,
Ilha Lee
,
Lorey K. Takahashi
Neuroscience
2007
The basolateral amygdala complex (BLA) and central amygdala nucleus (CeA) are involved in fear and anxiety. In addition, the BLA…Â
(More)
Is this relevant?
2006
2006
Proteomic analysis of rat hippocampus and frontal cortex after chronic treatment with fluoxetine or putative novel antidepressants: CRF1 and NK1 receptor antagonists.
Lucia Carboni
,
Miriam Vighini
,
Chiara Piubelli
,
Laura Castelletti
,
Alberto Milli
,
Enrico H Domenici
European neuropsychopharmacology : the journal of…
2006
Chronic administration of antidepressants is required for their efficacy, suggesting the involvement of long-term modifications…Â
(More)
Is this relevant?
2004
2004
Differential regulation of behavioral, genomic, and neuroendocrine responses by CRF infusions in rats.
B. M. Campbell
,
J. L. Morrison
,
E. L. Walker
,
K. Merchant
Pharmacology, biochemistry, and behavior
2004
Studies suggest that behavioral, genomic, and endocrine functions mediated by central corticotropin-releasing factor (CRF…Â
(More)
Is this relevant?
2004
2004
Antidepressant-like activity of corticotropin-releasing factor type-1 receptor antagonists in mice.
Darci M. Nielsen
,
Galen J. Carey
,
L. Gold
European journal of pharmacology
2004
The development of selective corticotropin-releasing factor type-1 (CRF1) receptor antagonists represents a potential novel…Â
(More)
Is this relevant?
2003
2003
Receptor occupancy of nonpeptide corticotropin-releasing factor 1 antagonist DMP696: correlation with drug exposure and anxiolytic efficacy.
Yu-Wen Li
,
Geraldine B. Hill
,
+10 authors
Robert Zazcek
The Journal of pharmacology and experimental…
2003
4-(1,3-Dimethoxyprop-2-ylamine)-2,7-dimethyl-8-(2,4-dichlorophenyl)-pyrazolo[1,5-a]-1,3,5-triazine (DMP696) is a highly selective…Â
(More)
Is this relevant?
2002
2002
Effects of a Non-peptide CRF Antagonist (DMP696) on the Behavioral and Endocrine Sequelae of Maternal Separation
C. Maciag
,
Gersham Dent
,
+5 authors
Mark A. Smith
Neuropsychopharmacology
2002
We examined whether blockade of corticotropin-releasing factor (CRF) receptors by a non-peptide CRF antagonist (DMP696) would…Â
(More)
Is this relevant?
2002
2002
The CRF1 receptor antagonist DMP696 produces anxiolytic effects and inhibits the stress-induced hypothalamic-pituitary-adrenal axis activation without sedation or ataxia in rats
John McElroy
,
Kathryn Anna Ward
,
+4 authors
Snjezana Lelas
Psychopharmacology
2002
Abstract Rationale. CRF1 antagonists may be effective in the treatment of anxiety disorders while having fewer side effects…Â
(More)
Is this relevant?
2000
2000
4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2, 4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF(1) receptor antagonist.
L. He
,
Paul J. Gilligan
,
+9 authors
Philipp Hartig
Journal of medicinal chemistry
2000
Structure-activity studies in the pyrazolo[1,5-a]-1,3,5-triazine series led to the discovery that compound 11i (DMP696) is a…Â
(More)
Is this relevant?